Grail Inc
NASDAQ:GRAL

Watchlist Manager
Grail Inc Logo
Grail Inc
NASDAQ:GRAL
Watchlist
Price: 18.35 USD 7.06% Market Closed
Market Cap: 616.6m USD
Have any thoughts about
Grail Inc?
Write Note

Grail Inc
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Grail Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Grail Inc
NASDAQ:GRAL
PP&E Net
$169.4m
CAGR 3-Years
42%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
PP&E Net
$5.1B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
PP&E Net
$5.4B
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
14%
Amgen Inc
NASDAQ:AMGN
PP&E Net
$6.2B
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
PP&E Net
$2.5B
CAGR 3-Years
23%
CAGR 5-Years
26%
CAGR 10-Years
13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
PP&E Net
$4.4B
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
18%
No Stocks Found

Grail Inc
Glance View

Market Cap
609.3m USD
Industry
Biotechnology

Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

GRAL Intrinsic Value
19.1 USD
Undervaluation 4%
Intrinsic Value
Price

See Also

What is Grail Inc's PP&E Net?
PP&E Net
169.4m USD

Based on the financial report for Dec 31, 2023, Grail Inc's PP&E Net amounts to 169.4m USD.

What is Grail Inc's PP&E Net growth rate?
PP&E Net CAGR 3Y
42%

Over the last year, the PP&E Net growth was -15%. The average annual PP&E Net growth rates for Grail Inc have been 42% over the past three years .

Back to Top